Jacobio Pharmaceuticals Group Co (HKSE:01167) EPS (Basic): HK$-0.21 (TTM As of Dec. 2025)


HKSE:01167 Jacobio Pharmaceuticals Group Co Ltd HKSE:01167
54 GF Score
Price HK$4.40
GF Value HK$2.05
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co EPS (Basic)?

Jacobio Pharmaceuticals Group Co HKSE:01167 +2.56% 54 EPS (Basic) is HK$-0.21 as of Dec. 2025. GuruFocus rates HKSE:01167 with a GF Score™ of 54/100 and a GF Value™ of HK$2.05 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Jacobio Pharmaceuticals Group Co's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was HK$-0.12. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.21.

Jacobio Pharmaceuticals Group Co's EPS (Diluted) for the six months ended in Dec. 2025 was HK$-0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.21.

Jacobio Pharmaceuticals Group Co's EPS without NRI for the six months ended in Dec. 2025 was HK$-0.15. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.24.

During the past 3 years, the average EPS without NRI Growth Rate was 24.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Jacobio Pharmaceuticals Group Co's highest 3-Year average EPS without NRI Growth Rate was 24.30% per year. The lowest was -51.90% per year. And the median was -0.45% per year.

Jacobio Pharmaceuticals Group Co  (HKSE:01167) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Jacobio Pharmaceuticals Group Co EPS (Basic) Related Terms

Jacobio Pharmaceuticals Group Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co EPS (Basic) Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -0.49 -0.55 -0.50 -0.21 -0.21

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.24 0.02 -0.09 -0.12
HKSE:01167
54GF Score
Jacobio Pharmaceuticals Group Co Ltd HKSE:01167
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jacobio Pharmaceuticals Group Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Jacobio Pharmaceuticals Group Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-161.269-0)/774.511
=-0.21

Jacobio Pharmaceuticals Group Co's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-96.097-0)/774.916
=-0.12

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of HK$-0.21 mean?
Jacobio Pharmaceuticals Group Co (HKSE:01167) has a EPS (Basic) of HK$-0.21 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Jacobio Pharmaceuticals Group Co and its competitors.
Is Jacobio Pharmaceuticals Group Co's EPS (Basic) too high?
Jacobio Pharmaceuticals Group Co's current EPS (Basic) is HK$-0.21. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's EPS (Basic) compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's EPS (Basic) of HK$-0.21 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Jacobio Pharmaceuticals Group Co and its competitors. Jacobio Pharmaceuticals Group Co's current EPS (Basic) is HK$-0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co (HKSE:01167) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$2.05, compared to a current price of HK$4.40 — trading 114.6% above its estimated fair value. The current EPS (Basic) is HK$-0.21. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (HKSE:01167), the current EPS (Basic) is HK$-0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (HKSE:01167) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of HK$4.40 is trading 114.6% above its estimated GF Value™ of HK$2.05. GuruFocus considers Jacobio Pharmaceuticals Group Co to be Significantly Overvalued.

Key valuation signals for HKSE:01167:

  • EPS (Basic): HK$-0.21
  • GF Value™: HK$2.05 vs. price of HK$4.40 (114.6% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the HKSE:01167 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for HKSE:01167

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$4.40
Price
HK$2.05
GF Value